IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 318 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 1.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2019 | $1,206,000 | -6.7% | 20,124 | 0.0% | 2.18% | +13.9% |
Q2 2019 | $1,293,000 | -20.8% | 20,124 | 0.0% | 1.91% | -13.6% |
Q1 2019 | $1,633,000 | +35.4% | 20,124 | -9.8% | 2.21% | -16.6% |
Q4 2018 | $1,206,000 | +0.4% | 22,307 | -4.2% | 2.65% | -7.4% |
Q3 2018 | $1,201,000 | +20.5% | 23,293 | -2.6% | 2.87% | +32.6% |
Q2 2018 | $997,000 | -2.3% | 23,916 | +3.4% | 2.16% | +8.0% |
Q1 2018 | $1,020,000 | -48.5% | 23,133 | -41.3% | 2.00% | +16.7% |
Q4 2017 | $1,981,000 | -11.6% | 39,388 | -10.9% | 1.71% | -14.7% |
Q3 2017 | $2,240,000 | +0.4% | 44,183 | +0.7% | 2.01% | -1.7% |
Q2 2017 | $2,232,000 | -29.6% | 43,867 | -44.4% | 2.04% | -13.1% |
Q1 2017 | $3,172,000 | -14.5% | 78,900 | +1.7% | 2.35% | -20.3% |
Q4 2016 | $3,709,000 | +32.4% | 77,550 | +1.5% | 2.96% | +88.1% |
Q3 2016 | $2,801,000 | +69.7% | 76,439 | +7.9% | 1.57% | -1.5% |
Q2 2016 | $1,651,000 | -57.9% | 70,868 | -26.8% | 1.60% | -47.4% |
Q1 2016 | $3,921,000 | -38.2% | 96,808 | -5.5% | 3.03% | -27.7% |
Q4 2015 | $6,345,000 | – | 102,459 | – | 4.19% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sicart Associates LLC | 367,360 | $14,768,000 | 10.67% |
BB BIOTECH AG | 7,461,295 | $299,944,000 | 9.81% |
TANAKA CAPITAL MANAGEMENT INC | 83,399 | $3,353,000 | 7.39% |
DOWLING & YAHNKE LLC | 675,843 | $27,169,000 | 2.89% |
Opus Point Partners Management, LLC | 78,900 | $3,172,000 | 2.35% |
Motley Fool Asset Management LLC | 259,000 | $10,412,000 | 2.25% |
ARK Investment Management | 127,563 | $5,128,000 | 1.48% |
Motley Fool Wealth Management, LLC | 325,965 | $13,104,000 | 1.26% |
PINNACLE ASSOCIATES LTD | 1,514,710 | $60,891,000 | 1.16% |
Bellevue Group AG | 205,253 | $8,251,000 | 1.10% |